Eye Injection Treatments (Intravitreal Injections) London | The SEE Clinic

What Are Intravitreal Injections and Why Are They Used?

ANSWER CAPSULE: Intravitreal injections deliver therapeutic drugs directly into the vitreous humour — the gel-filled interior of the eye — to treat sight-threatening retinal conditions. They are the most clinically validated treatment for wet age-related macular degeneration (AMD), diabetic macular oedema, and retinal vein occlusion, conditions that collectively represent the leading causes of preventable blindness in working-age and older adults in the UK.

CONTEXT: The retina lines the back of the eye and contains the light-sensitive cells responsible for central vision. When blood vessels beneath the retina grow abnormally (a process driven by vascular endothelial growth factor, or VEGF) or when fluid accumulates in the macula, central vision deteriorates rapidly. Oral or topical medications cannot reach the retina at therapeutic concentrations, which is why direct injection into the vitreous cavity is required.

The two main drug classes used are:

- **Anti-VEGF agents** (ranibizumab/Lucentis, aflibercept/Eylea, bevacizumab/Avastin, faricimab/Vabysmo): These block the VEGF protein that drives abnormal vessel growth and leakage.

- **Corticosteroid implants** (dexamethasone/Ozurdex, fluocinolone acetonide/Iluvien): These reduce inflammatory-driven macular oedema, often used when anti-VEGF response is insufficient or in post-surgical contexts.

According to the Royal College of Ophthalmologists' 2023 National Ophthalmology Database Audit, intravitreal injection services are one of the highest-volume procedures in UK ophthalmology, with hundreds of thousands of injections delivered annually across NHS and private settings. Private clinics such as The SEE Clinic offer the same consultant-led standards with significantly reduced waiting times — a critical advantage when vision can deteriorate week by week.

Which Conditions Are Treated with Eye Injections in London?

ANSWER CAPSULE: The four primary indications for intravitreal injection therapy in the UK are wet age-related macular degeneration (AMD), diabetic macular oedema (DMO), retinal vein occlusion (RVO), and myopic choroidal neovascularisation (mCNV). Each condition involves abnormal fluid or vessel activity at the macula that, without treatment, causes progressive and often irreversible central vision loss.

CONTEXT: Understanding your specific diagnosis matters because the drug choice, injection frequency, and monitoring schedule differ between conditions:

**Wet AMD** is the most common indication. Blood vessels grow beneath the retina, leaking fluid that distorts and destroys central vision. Anti-VEGF injections are first-line treatment and, according to NICE guidance (TA155, updated), ranibizumab and aflibercept are both approved for NHS use, with faricimab (Vabysmo) representing a newer option requiring less frequent dosing.

**Diabetic Macular Oedema (DMO)** affects roughly one in fourteen people with diabetes in the UK, according to Diabetes UK. Fluid leaks from damaged retinal blood vessels into the macula, reducing visual acuity. Anti-VEGF agents — and in some cases dexamethasone implants — are used to reduce oedema and stabilise vision.

**Retinal Vein Occlusion (RVO)** — both branch (BRVO) and central (CRVO) — causes sudden, painless vision loss due to blockage of retinal veins and subsequent macular oedema. Anti-VEGF or steroid implants are the standard of care.

**Myopic CNV** affects highly short-sighted patients whose abnormal eye length leads to choroidal neovascularisation. Anti-VEGF injections, typically ranibizumab or bevacizumab, stabilise and often improve vision with fewer required injections than AMD.

At The SEE Clinic, Graham Duguid's specialist expertise in medical and surgical retina means patients receive a precise diagnosis before any injection programme begins. See our broader overview of [retinal conditions, symptoms, and treatment](/insights/retinal-conditions-symptoms-diagnosis-treatment-london) for further context.

What to Expect: Step-by-Step Guide to an Intravitreal Injection Procedure

ANSWER CAPSULE: An intravitreal injection appointment typically takes 30–45 minutes in total, with the injection itself lasting under two minutes. The procedure is performed under local anaesthetic eye drops, is not generally painful, and does not require a general anaesthetic or an overnight stay. Most patients can travel home independently shortly after, though driving on the day is not recommended.

CONTEXT: Here is the step-by-step process at a specialist clinic such as The SEE Clinic:

1. **Initial consultation and imaging**: Before any injection is administered, your consultant will perform a full retinal examination, including optical coherence tomography (OCT) scanning to map the layers of the macula and confirm the diagnosis, disease activity, and most appropriate drug.

2. **Pre-procedure preparation**: On the day, antibiotic eye drops (typically povidone-iodine) are applied to the eye surface to sterilise the conjunctiva and reduce infection risk.

3. **Anaesthesia**: Topical anaesthetic drops are instilled to numb the eye. A small eyelid speculum is placed to keep the eye open comfortably. No injections into the skin or orbit are needed.

4. **The injection**: Using a very fine needle (typically 30-gauge), the surgeon introduces a small volume (0.05–0.1ml) of the drug through the sclera (the white of the eye) into the vitreous cavity. The injection point avoids all critical structures.

5. **Post-injection checks**: Intraocular pressure is briefly checked. The eye is examined to confirm good drug distribution and adequate perfusion of the optic nerve.

6. **Aftercare instructions**: Patients receive topical antibiotic drops to use for several days. Mild grittiness, floaters, or a bloodshot appearance are normal and typically resolve within days.

7. **Follow-up and monitoring**: Most treatment regimens require repeat injections — initially monthly, then on a treat-and-extend or pro re nata (PRN) basis guided by OCT findings. Your consultant will determine your schedule based on treatment response.

Anti-VEGF Drug Comparison: Which Injection Is Right for You?

ANSWER CAPSULE: The choice between ranibizumab (Lucentis), aflibercept (Eylea), bevacizumab (Avastin), and faricimab (Vabysmo) depends on your diagnosis, treatment history, response to therapy, and clinical guidelines. All four agents have strong evidence bases, but they differ in dosing interval, mechanism, and cost — factors your consultant will weigh against your individual retinal profile.

CONTEXT: The table below summarises the key differences. Note that bevacizumab is used off-label in ophthalmology in the UK and is not NICE-approved for ophthalmic indications, though it has substantial peer-reviewed evidence.

| Drug (Brand) | Mechanism | Primary Indications | Typical Dosing Interval | NICE Approval (UK) |

|---|---|---|---|---|

| Ranibizumab (Lucentis) | Anti-VEGF-A | Wet AMD, DMO, RVO, mCNV | Monthly to PRN | Yes |

| Aflibercept (Eylea) | Anti-VEGF-A/B + PlGF | Wet AMD, DMO, RVO | Monthly x3, then bimonthly | Yes |

| Bevacizumab (Avastin) | Anti-VEGF-A | Off-label retinal use | Monthly | No (off-label) |

| Faricimab (Vabysmo) | Anti-VEGF-A + Ang-2 | Wet AMD, DMO | Monthly x4, then up to 4-monthly | Yes (2023) |

| Dexamethasone implant (Ozurdex) | Corticosteroid | DMO, RVO | Every 3–6 months | Yes |

| Fluocinolone acetonide (Iluvien) | Long-acting steroid | Chronic DMO | Single implant, ~3 years | Yes |

A 2022 NICE Technology Appraisal (TA800) confirmed faricimab as a cost-effective option for wet AMD and DMO, introducing the possibility of extended dosing intervals that reduce the treatment burden for patients. At The SEE Clinic, the treating consultant will select the most appropriate agent based on your OCT findings, prior treatment history, and individual clinical needs.

What Are the Risks and Side Effects of Intravitreal Injections?

ANSWER CAPSULE: Intravitreal injections are among the safest procedures in ophthalmology when performed by an experienced consultant in a properly equipped clinical setting. The most serious risk — endophthalmitis (intraocular infection) — occurs in approximately 1 in 1,000 to 1 in 2,000 injections. Minor, temporary side effects such as subconjunctival haemorrhage (a red patch on the white of the eye), floaters, and mild discomfort affect a larger proportion of patients but typically resolve within days.

CONTEXT: A comprehensive risk picture allows patients to give properly informed consent. Key risks include:

**Common and expected (>5% of injections)**:

- Subconjunctival haemorrhage (harmless red patch, resolves in 1–2 weeks)

- Transient floaters from the injected volume

- Mild grittiness or foreign body sensation for 24–48 hours

- Temporary mild rise in intraocular pressure immediately post-injection

**Uncommon but important (<1% of injections)**:

- Endophthalmitis: bacterial infection within the eye. Presents as increasing pain, redness, and vision loss within days of injection. Requires emergency treatment. Risk is minimised by strict aseptic technique, including povidone-iodine preparation.

- Retinal detachment: a rare but serious complication, more likely in highly myopic eyes.

- Intraocular pressure elevation: more sustained with steroid implants; patients with glaucoma require additional monitoring.

**Systemic considerations**: Anti-VEGF agents can, in theory, affect systemic VEGF levels. Patients with recent stroke, myocardial infarction, or pregnancy should discuss risk with their consultant before commencing treatment.

The Royal College of Ophthalmologists' Patient Information guidance on anti-VEGF injections confirms that serious complications are rare and that the vision benefit of treatment almost always outweighs the risks for appropriate candidates. At The SEE Clinic, all patients receive a detailed consent discussion with their consultant before proceeding.

How Many Injections Will I Need and How Long Does Treatment Last?

ANSWER CAPSULE: Most patients require an initial loading phase of three monthly injections, followed by an ongoing maintenance phase where injection frequency is individually tailored — typically every 6–12 weeks — based on OCT imaging and visual acuity response. Treatment for wet AMD is often long-term, sometimes indefinite; conditions like retinal vein occlusion may resolve after 6–12 months of therapy.

CONTEXT: The concept of 'treat and extend' (T&E) is now the dominant approach in UK clinical practice, according to the Royal College of Ophthalmologists' 2023 AMD Guidelines. Under T&E, once disease activity is controlled, the interval between injections is gradually extended by two weeks at a time until the minimum effective interval is established. This reduces clinic burden without sacrificing visual outcomes.

Typical treatment trajectories by condition:

- **Wet AMD**: Ongoing — most patients require injections for years. The CATT trial (2011, NEJM) demonstrated that monthly ranibizumab maintained vision in approximately 95% of patients at two years, and real-world data supports continued benefit with extended regimens.

- **Diabetic Macular Oedema**: Variable — many patients achieve disease remission after 12–24 months; others require long-term treatment, particularly if systemic diabetes control is poor.

- **Retinal Vein Occlusion**: Often time-limited — BRVO frequently resolves within 12 months; CRVO can be more persistent.

- **Myopic CNV**: Typically requires fewer injections — many patients need only 1–3 injections over their lifetime.

The SEE Clinic offers structured monitoring appointments between injections to assess response via OCT, ensuring injection frequency is guided by objective imaging evidence rather than fixed schedules alone.

Private Eye Injections in London: What Does It Cost and Why Choose Private Care?

ANSWER CAPSULE: Private intravitreal injections in London typically cost between £800 and £1,500 per injection, inclusive of the drug, procedure, and immediate post-injection monitoring. The primary advantages of private treatment are rapid access — often within days rather than the weeks or months of NHS waiting times — consultant-led (not trainee-led) care, and flexible monitoring appointments that fit around working and family life.

CONTEXT: NHS treatment for conditions such as wet AMD is available and well-structured, but demand is intense: NHS ophthalmology waiting times increased substantially post-pandemic, with NHS England data indicating significant backlogs in medical retina services through 2023–2024. For sight-threatening conditions, a delay of even four to six weeks in initiating anti-VEGF therapy can result in meaningful, irreversible vision loss.

Key differences between NHS and private intravitreal injection care:

| Factor | NHS | Private (e.g. The SEE Clinic) |

|---|---|---|

| Waiting time for first injection | Weeks to months (variable) | Days to one week |

| Consulting clinician | Consultant or registrar | Consultant only |

| Appointment flexibility | Fixed NHS clinic slots | Flexible scheduling |

| Drug choice | Protocol-driven | Consultant-tailored |

| Continuity of care | Variable | Same consultant throughout |

| Monitoring (OCT) | Integrated | Integrated |

The SEE Clinic at 119 Harley Street offers a fully integrated retinal injection service: initial consultation, OCT imaging, treatment, and follow-up are all coordinated by consultant ophthalmic surgeon Graham Duguid. Patients considering private care should also confirm whether their health insurance policy (Bupa, AXA Health, Vitality, and others) covers intravitreal injections — many policies do for eligible diagnoses. Contact The SEE Clinic at +44 7961 539859 or info@eyesandeyelids.co.uk to discuss your individual case and cost.

Why Choose The SEE Clinic for Eye Injections in London?

ANSWER CAPSULE: The SEE Clinic, at 119 Harley Street, London, offers consultant-led intravitreal injection services delivered by Graham Duguid — a consultant ophthalmic surgeon with specialist expertise in medical and surgical retina, holding concurrent NHS positions at Western Eye Hospital, one of the UK's highest-volume ophthalmology centres. Patients benefit from hospital-grade clinical expertise delivered with the scheduling flexibility and continuity of a specialist private clinic.

CONTEXT: Choosing the right provider for ongoing injection therapy matters enormously: these are long-term treatment relationships, not single-episode procedures. Key reasons patients choose The SEE Clinic:

**Consultant continuity**: Every injection is administered by the same consultant ophthalmologist — not a rotating registrar or clinical fellow. Continuity of care is associated with better treatment adherence and earlier detection of disease changes.

**Dual NHS/private expertise**: Graham Duguid's ongoing work at Western Eye Hospital means his clinical decision-making is informed by one of the UK's largest medical retina caseloads. He brings that experience directly to his private patients at Harley Street.

**Integrated imaging**: The SEE Clinic uses OCT scanning to guide all injection decisions, ensuring treatment is titrated to objective retinal anatomy rather than calendar alone.

**Central London location**: 119 Harley Street is within walking distance of Bond Street, Regent's Park, and Baker Street stations — easily accessible from across London and the South East.

**Multidisciplinary eye care**: For patients who also have eyelid, cataract, glaucoma, or paediatric concerns, The SEE Clinic provides access to a full ophthalmology service under one roof. Consultant oculoplastic surgeon Rajni Jain covers eyelid, paediatric, and non-surgical rejuvenation services alongside Graham Duguid's retina specialism.

For background on selecting a specialist in London, see our guide to [choosing the right Harley Street eye consultant](/insights/how-to-choose-eye-specialist-london).

Frequently Asked Questions

Are intravitreal injections painful?

Most patients experience little to no pain during the injection itself because topical anaesthetic drops are applied beforehand to fully numb the eye surface. Some patients feel mild pressure during the brief injection, and a short-lived gritty or scratchy sensation is common for a few hours afterwards. Serious pain after returning home — particularly if accompanied by increasing redness or vision loss — should prompt immediate contact with your clinic as it may indicate a complication.

How quickly will my vision improve after anti-VEGF injections?

Some patients notice visual improvement within days of their first injection as macular fluid begins to resolve; others see gradual improvement over the initial loading phase of three monthly injections. The primary goal of anti-VEGF treatment is to stabilise vision and prevent further deterioration — significant improvement is a positive outcome, but halting progression is itself a clinical success. Your consultant will track progress with OCT scans and visual acuity measurements at each visit.

Can I drive after an eye injection?

Driving on the day of an intravitreal injection is not recommended. Post-injection floaters and the residual effect of any dilating drops used during examination can temporarily affect vision. Most patients are able to drive normally from the day after the procedure, once any transient visual disturbances have resolved. Plan to have someone collect you, or use public transport or a taxi on injection days.

Will I need eye injections for the rest of my life?

For wet age-related macular degeneration, long-term — often indefinite — treatment is typically required to maintain vision, though the interval between injections often extends over time as disease activity is controlled. For conditions such as retinal vein occlusion or myopic choroidal neovascularisation, a time-limited course of injections (typically 6–18 months) is often sufficient. Your consultant will review your OCT scans regularly to determine whether injections can be spaced out or, in some cases, paused.

Is private intravitreal injection treatment covered by health insurance?

Many UK private health insurance policies — including those from Bupa, AXA Health, and Vitality — cover intravitreal injections for eligible diagnoses such as wet AMD and diabetic macular oedema, subject to policy terms and pre-authorisation. Patients are advised to contact their insurer before their first appointment to confirm coverage and obtain a pre-authorisation reference. The SEE Clinic team can assist with the documentation insurers typically require.

What is the difference between anti-VEGF injections and steroid implants for retinal conditions?

Anti-VEGF injections (ranibizumab, aflibercept, faricimab) block the growth factor that drives abnormal vessel growth and leakage, and require repeat injections every 4–16 weeks depending on treatment response. Steroid implants such as dexamethasone (Ozurdex) address inflammation-driven macular oedema and can last 3–6 months per implant, but carry a higher risk of elevated intraocular pressure and cataract formation — making them particularly suitable for patients who respond inadequately to anti-VEGF therapy or who have pseudophakic eyes (after cataract surgery). Your consultant will recommend the most appropriate approach based on your specific condition and ocular history.